Imaging Biomarkers for Friedreich’s Ataxia Clinical Trials
An overview of the use of MRI and DTI imaging biomarkers for Friedreich’s ataxia (FRDA) in research studies & multi-center clinical trials.
Neuroimaging in Frontotemporal Dementia & Clinical Trials
The utility of MRI & PET imaging biomarkers in our understanding of Frontotemporal Dementia (FTD) variants, and their use as endpoints in FTD clinical trials.
MRI Gadolinium-Enhancing Lesions in MS Clinical Trials
How gadolinium (Gd) enhancing lesions are used to track disease progression & response to therapeutic intervention in multiple sclerosis (MS) clinical trials.
MRI in Clinical Trials of Multiple System Atrophy (MSA)
This resource provides an overview of the utility of volumetric MRI and diffusion-weighted imaging (DWI) as biomarkers in research studies of MSA.
Imaging Biomarkers to Distinguish CBD from Other Tauopathies
Overview of brain imaging biomarkers to identify Corticobasal Degeneration (CBD) subjects and their use in clinical trials of disease-modifying therapeutics.
Longitudinal Change in Tau PET in MCI & Alzheimer’s Disease
An overview of the natural history of change in Tau PET tracer uptake & binding in Mild Cognitive Impairment (MCI) & Alzheimer’s disease (AD).
Imaging Biomarkers for Progressive Supranuclear Palsy (PSP)
An overview of the various brain imaging methods (MRI, PET, SPECT) available to assess efficacy of disease-modifying therapeutics in clinical trials of PSP.